Last checked at 1 Mar 2024 15:00
01 March 2024
Physiomics plc
("Physiomics" or "the Company")
Notice of Results and Investor Presentation
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it will be posting its interim results on Thursday 7 March 2024.
The Company will provide a live presentation update in-line with these results via Investor Meet Company on 18 March 2024 at 12:00 pm GMT. During this presentation, Peter Sargent (CEO) and Jim Millen (Chairman) would be happy to take questions relating to the Company's interim results and more broadly about the business.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 17 March 2024, 09:00 am GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet PHYSIOMICS PLC via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
Investors who already follow PHYSIOMICS PLC on the Investor Meet Company platform will automatically be invited.
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour? technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.